{
    "data": [
        {
            "id": 2991636,
            "title": "Desjardins Sticks to Their Buy Rating for Royal Bank Of Canada (RY)",
            "description": "<html><head></head><body><p>Desjardins analyst  maintained a Buy rating on Royal Bank Of Canada today and set a price target of C$250.00.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p></p>\n<p>In addition to Desjardins, Royal Bank Of Canada also received a Buy from Canaccord Genuity’s Matthew Lee in a report issued today. However, on the same day, CIBC maintained a Hold rating on Royal Bank Of Canada (NYSE: RY).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_574713295-2-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/desjardins-sticks-to-their-buy-rating-for-royal-bank-of-canada-ry-blurbs-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:16:33",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991637,
            "title": "Granite Real Estate (GRT.UN) Gets a Buy from TD Cowen",
            "description": "<html><head></head><body><p>TD Cowen analyst  maintained a Buy rating on Granite Real Estate today and set a price target of C$96.00.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p></p>\n<p>Granite Real Estate has an analyst consensus of Strong Buy, with a price target consensus of C$98.33.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/shutterstock_261540053-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/granite-real-estate-grt-un-gets-a-buy-from-td-cowen-blurbs-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:16:44",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991830,
            "title": "Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating",
            "description": "<html><head></head><body><p><a href=\"https://www.tipranks.com/experts/analysts/ritu-baral\" target=\"_blank\" style=\"color:blue\">Ritu Baral</a>, an analyst from TD Cowen, maintained the Buy rating on Vera Therapeutics. The associated price target remains the same with $73.00.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Ritu Baral has given his Buy rating due to a combination of factors tied to Vera Therapeutics’ lead asset, atacicept, and its late‑stage regulatory position in IgA nephropathy. The drug now has a July 7 PDUFA date with priority review, and Baral appears to view approval as highly likely, supported by Phase 3 data showing a robust, statistically meaningful reduction in proteinuria versus placebo.<br>\n<br>\nBaral also emphasizes Vera’s strong commercial setup and financial position, which together support a successful launch if approval is granted. The planned sales force buildout targeting a majority of U.S. nephrologists, the expectation of a broad label comparable to Voyxact without proteinuria restrictions, and potential pricing in line with the high benchmark set by that competitor all underpin her favorable view of revenue potential and justify the Buy recommendation.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1931544818-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/vera-therapeutics-strong-atacicept-phase-3-data-and-favorable-regulatory-commercial-setup-support-buy-rating-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 06:45:26",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991856,
            "title": "Balanced Risk-Reward and Limited Visibility Justify Hold Rating on SkyWater Ahead of IonQ Acquisition",
            "description": "<html><head></head><body><p>In a report released today, <a href=\"https://www.tipranks.com/experts/analysts/krish-sankar\" target=\"_blank\" style=\"color:blue\">Krish Sankar</a> from TD Cowen maintained a Hold rating on SkyWater Technology, with a price target of <span id=\"expert-recommendation-target\">$35.00</span>.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Krish Sankar has given his Hold rating due to a combination of factors, including slightly better-than-expected quarterly revenue and EPS performance contrasted with a weaker-than-expected gross margin profile. The company reported solid top-line growth and modest EPS upside versus prior estimates, but profitability metrics lag, tempering the near-term upside case.</p>\n<p>At the same time, SkyWater did not provide forward guidance because of the pending acquisition by IonQ, which limits visibility into standalone fundamentals and makes it harder to underwrite a more decisive rating change. Given the ongoing quantum-related ATS engagements, progress in advanced packaging, and a valuation anchored around roughly 3x projected CY26 sales, Sankar concludes that risk and reward appear balanced, justifying a Hold stance.\n</p>\n<p>In another report released today, TipRanks – OpenAI also downgraded the stock to a Hold with a $34.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2168579375-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/balanced-risk-reward-and-limited-visibility-justify-hold-rating-on-skywater-ahead-of-ionq-acquisition-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 07:05:24",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991638,
            "title": "Raymond James Remains a Buy on Royal Bank Of Canada (RY)",
            "description": "<html><head></head><body><p>In a report released today, <a href=\"https://www.tipranks.com/experts/analysts/stephen-boland\" target=\"_blank\" style=\"color:blue\">Stephen Boland</a> from Raymond James maintained a Buy rating on Royal Bank Of Canada, with a price target of <span id=\"expert-recommendation-target\">C$260.00</span>.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Boland covers the Financial sector, focusing on stocks such as Toronto Dominion Bank, Bank Of Nova Scotia, and Canadian Bank of Commerce. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Boland has an average return of <span style=\"color:green;font-weight:bold;\">5.5%</span> and a 53.04% success rate on recommended stocks. </p>\n<p>In addition to Raymond James, Royal Bank Of Canada also received a Buy from Canaccord Genuity’s Matthew Lee in a report issued today. However, on the same day, CIBC maintained a Hold rating on Royal Bank Of Canada (NYSE: RY).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1020878011-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/raymond-james-remains-a-buy-on-royal-bank-of-canada-ry-blurbs-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:16:55",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991639,
            "title": "Royal Bank Of Canada (RY) Gets a Buy from National Bank",
            "description": "<html><head></head><body><p>In a report released today, <a href=\"https://www.tipranks.com/experts/analysts/gabriel-dechaine\" target=\"_blank\" style=\"color:blue\">Gabriel Dechaine</a> from National Bank maintained a Buy rating on Royal Bank Of Canada, with a price target of <span id=\"expert-recommendation-target\">C$247.00</span>.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Dechaine covers the Financial sector, focusing on stocks such as Toronto Dominion Bank, Canadian Bank of Commerce, and Royal Bank Of Canada. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Dechaine has an average return of <span style=\"color:green;font-weight:bold;\">9.9%</span> and a 68.60% success rate on recommended stocks. </p>\n<p>In addition to National Bank, Royal Bank Of Canada also received a Buy from Canaccord Genuity’s Matthew Lee in a report issued today. However, on the same day, CIBC maintained a Hold rating on Royal Bank Of Canada (NYSE: RY).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1326553091-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/royal-bank-of-canada-ry-gets-a-buy-from-national-bank-blurbs-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:17:08",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991641,
            "title": "RBC Capital Sticks to Their Buy Rating for Stantec (STN)",
            "description": "<html><head></head><body><p>In a report released today, <a href=\"https://www.tipranks.com/experts/analysts/sabahat-khan\" target=\"_blank\" style=\"color:blue\">Sabahat Khan</a> from <a data-autolink=\"true\" href=\"https://www.tipranks.com/experts/firms/rbc-capital\">RBC Capital</a> maintained a Buy rating on Stantec, with a price target of <span id=\"expert-recommendation-target\">C$175.00</span>.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Khan is a 5-star analyst with an average return of <span style=\"color:green;font-weight:bold;\">8.3%</span> and a 54.11% success rate. Khan covers the Industrials sector, focusing on stocks such as Deere, RB Global, and Finning International.</p>\n<p>In addition to RBC Capital, Stantec also received a Buy from Desjardins’s Benoit Poirier in a report issued today. However, on the same day, ATB Cormark Capital Markets maintained a Hold rating on Stantec (NYSE: STN).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Industrials-7-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-stantec-stn-blurbs-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:17:19",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991694,
            "title": "Hold Rating on Agilon: Margin Improvement Efforts Tempered by Persistent Profitability and Cost Pressures",
            "description": "<html><head></head><body><p>In a report released today, <a href=\"https://www.tipranks.com/experts/analysts/ryan-langston\" target=\"_blank\" style=\"color:blue\">Ryan Langston</a> from TD Cowen maintained a Hold rating on Agilon Health, with a price target of <span id=\"expert-recommendation-target\">$0.60</span>.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Ryan Langston has given his Hold rating due to a combination of factors, including weaker-than-expected recent results and only gradual progress toward profitability. The company’s latest quarter showed a larger adjusted EBITDA loss than forecast, and management anticipates a meaningful decline in total membership next year, even as they target roughly breakeven EBITDA in 2026.</p>\n<p>At the same time, Langston recognizes that Agilon is taking steps to improve margins through better Medicare Advantage pricing, more favorable payer contracts, and reduced Part D exposure, supported by a liquidity runway that appears adequate through the transition. However, he remains wary of ongoing medical cost <a data-autolink=\"true\" href=\"https://www.tipranks.com/economic-indicators/inflation-rate\">inflation</a>, potential adverse prior-year development, and lower profitability from ACO REACH lives, which together justify a sharply reduced price target and a neutral, rather than more optimistic, stance.<br>\n</p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Langston is an analyst with an average return of <span style=\"color:red;font-weight:bold;\">-5.7%</span> and a 39.82% success rate. Langston covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, Centene, and HCA Healthcare.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1061972606-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/hold-rating-on-agilon-margin-improvement-efforts-tempered-by-persistent-profitability-and-cost-pressures-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:45:21",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991695,
            "title": "NIQ: Buy Rating on Improving Fundamentals, Margin Expansion, and Undervalued Share Price in an AI-Driven Market",
            "description": "<html><head></head><body><p>William Blair analyst <a href=\"https://www.tipranks.com/experts/analysts/andrew-nicholas\" target=\"_blank\" style=\"color:blue\">Andrew Nicholas</a> has maintained their bullish  stance on <span class=\"tr-stock-ticker\" style=\"color:blue; font-weight:bold\"><a href=\"https://www.tipranks.com/stocks/niq\" target=\"_blank\" ;=\"\" rel=\"nofollow\">NIQ</a></span> stock, giving a Buy rating on February 17.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Andrew Nicholas has given his Buy rating due to a combination of factors tied to NIQ’s operating momentum and margin trajectory. The company delivered fourth-quarter revenue and adjusted EBITDA ahead of his expectations, helped by favorable currency movements and slightly stronger organic growth, while initial 2026 guidance signals notable profitability improvement despite the near-term EPS shortfall.</p>\n<p>He also sees the recent share price weakness as overdone relative to the company’s improving fundamentals and margin expansion prospects. In his view, NIQ’s refreshed leadership team, ongoing technology modernization, and sharpened go-to-market approach should sustain solid growth and enhance its competitive position, ultimately supporting both earnings upside and valuation multiple catch-up versus information services peers in an increasingly <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a>-driven landscape.</p>\n<p>In another report released on February 17, Bank of America Securities also maintained a Buy rating on the stock with a $20.00 price target.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_137090738-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/niq-buy-rating-on-improving-fundamentals-margin-expansion-and-undervalued-share-price-in-an-ai-driven-market-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:45:29",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991668,
            "title": "Alignment Healthcare: Conservative Guidance, Solid EBITDA Trajectory, and Limited Regulatory Risk Support Buy Rating and $25 Target",
            "description": "<html><head></head><body><p>Analyst <a href=\"https://www.tipranks.com/experts/analysts/ryan-langston\" target=\"_blank\" style=\"color:blue\">Ryan Langston</a> of TD Cowen reiterated a Buy rating on Alignment Healthcare, retaining the price target of $25.00.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Ryan Langston has given his Buy rating due to a combination of factors, including stronger-than-expected recent EBITDA performance and management’s history of issuing cautious guidance that often proves conservative. He notes that the company’s 2026 EBITDA outlook aligns with prior commentary, and his modest upward revision to future EBITDA reinforces confidence in the earnings trajectory and supports maintaining a $25 price target based on 2027 enterprise value to revenue.</p>\n<p>Langston also highlights that Alignment Healthcare appears well positioned against regulatory changes, with minimal risk exposure to chart-review coding and a view that proposed Stars and measure adjustments should be largely neutral over time. He further underscores that expected medical loss ratio seasonality is already reflected in guidance, suggesting that near-term volatility is manageable and that the long-term growth and profitability profile justifies a Buy recommendation.\n</p>\n<p>In another report released today, TipRanks – Google also reiterated a Buy rating on the stock with a $23.50 price target.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2170812299-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/alignment-healthcare-conservative-guidance-solid-ebitda-trajectory-and-limited-regulatory-risk-support-buy-rating-and-25-target-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:35:24",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991642,
            "title": "National Bank Sticks to Their Buy Rating for Stantec (STN)",
            "description": "<html><head></head><body><p>National Bank analyst  maintained a Buy rating on Stantec today and set a price target of C$163.00.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p></p>\n<p>In addition to National Bank, Stantec also received a Buy from <a data-autolink=\"true\" href=\"https://www.tipranks.com/experts/firms/rbc-capital\">RBC Capital</a>’s Sabahat Khan in a report issued today. However, on the same day, ATB Cormark Capital Markets maintained a Hold rating on Stantec (NYSE: STN).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Industrials-9-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/national-bank-sticks-to-their-buy-rating-for-stantec-stn-blurbs-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:17:31",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991643,
            "title": "Canadian Bank of Commerce (CM) Gets a Hold from Raymond James",
            "description": "<html><head></head><body><p>In a report released today, <a href=\"https://www.tipranks.com/experts/analysts/stephen-boland\" target=\"_blank\" style=\"color:blue\">Stephen Boland</a> from Raymond James maintained a Hold rating on Canadian Bank of Commerce, with a price target of <span id=\"expert-recommendation-target\">C$148.50</span>.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Boland is a 4-star analyst with an average return of <span style=\"color:green;font-weight:bold;\">5.5%</span> and a 53.04% success rate. Boland covers the Financial sector, focusing on stocks such as Toronto Dominion Bank, Bank Of Nova Scotia, and Canadian Bank of Commerce.</p>\n<p>In addition to Raymond James, Canadian Bank of Commerce also received a Hold from National Bank’s Gabriel Dechaine in a report issued today. However, on the same day, <a data-autolink=\"true\" href=\"https://www.tipranks.com/experts/firms/rbc-capital\">RBC Capital</a> maintained a Buy rating on Canadian Bank of Commerce (NYSE: CM).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_593873471-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/canadian-bank-of-commerce-cm-gets-a-hold-from-raymond-james-blurbs-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 05:17:41",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991603,
            "title": "Biodesix: Strengthened Balance Sheet, Expanding Sales Force, and Modest Revenue Outperformance Support Buy Rating at Attractive 1x Sales Valuation",
            "description": "<html><head></head><body><p>Biodesix, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst <a href=\"https://www.tipranks.com/experts/analysts/daniel-brennan\" target=\"_blank\" style=\"color:blue\">Daniel Brennan</a> from TD Cowen reiterated a Buy rating on the stock and has a $30.00 price target.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Daniel Brennan has given his Buy rating due to a combination of factors including revenue guidance, sales force expansion, and improved financial strength. Management’s 2026 revenue outlook modestly exceeds consensus, and with a planned increase of 24 sales representatives on top of already solid per‑rep productivity near $1M, he sees credible potential for revenue to outperform current expectations.</p>\n<p>Brennan also highlights that Biodesix has recently bolstered its balance sheet through an at‑the‑market equity raise, bringing pro forma cash to roughly $33.7M and easing liquidity concerns. The company’s achievement of adjusted EBITDA profitability in Q4 further reduces worries around cash burn, and with the stock trading at about 1x sales in an underpenetrated market, he views the current valuation as an appealing entry point for investors.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1911898180-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/biodesix-strengthened-balance-sheet-expanding-sales-force-and-modest-revenue-outperformance-support-buy-rating-at-attractive-1x-sales-valuation-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 04:55:22",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991561,
            "title": "Amneal Pharmaceuticals: Portfolio Shift to High-Margin Brands and Biosimilars Supports Buy Rating and Upside to $17 Target",
            "description": "<html><head></head><body><p>In a report released today, <a href=\"https://www.tipranks.com/experts/analysts/les-sulewski\" target=\"_blank\" style=\"color:blue\">Les Sulewski</a> from Truist Financial maintained a Buy rating on Amneal Pharmaceuticals, with a price target of <span id=\"expert-recommendation-target\">$17.00</span>.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Les Sulewski has given his Buy rating due to a combination of factors that underscore improving earnings power and disciplined execution. Management is deliberately shifting the portfolio away from lower-margin distribution activities toward higher-margin branded, complex generic, and biosimilar products, which is expected to drive EBITDA growth meaningfully faster than sales through 2026 and beyond.</p>\n<p>Crexont is demonstrating strong early adoption, with rising market share, favorable adherence, and a clear path to materially higher patient counts and revenue, while additional Phase 4 data and planned international launches support a longer growth runway. At the same time, a robust pipeline of complex generics and biosimilars, including the high-potential bXolair opportunity, positions Amneal for incremental upside, and the recent share pullback makes the risk‑reward especially attractive relative to the newly increased $17 price target.</p>\n<p>Sulewski covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Cormedix, and Viatris. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Sulewski has an average return of <span style=\"color:green;font-weight:bold;\">9.5%</span> and a 47.27% success rate on recommended stocks. </p>\n<p>In another report released on February 11, J.P. Morgan also maintained a Buy rating on the stock with a $18.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2162340203-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/amneal-pharmaceuticals-portfolio-shift-to-high-margin-brands-and-biosimilars-supports-buy-rating-and-upside-to-17-target-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 04:35:26",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991545,
            "title": "Via: Strong Operating Momentum, Defensible AI-Driven Transit Platform, and Expanding Growth Opportunities Justify Buy Rating",
            "description": "<html><head></head><body><p>William Blair analyst <a href=\"https://www.tipranks.com/experts/analysts/jonathan-ho\" target=\"_blank\" style=\"color:blue\">Jonathan Ho</a> has maintained their bullish  stance on <span class=\"tr-stock-ticker\" style=\"color:blue; font-weight:bold\"><a href=\"https://www.tipranks.com/stocks/via\" target=\"_blank\" ;=\"\" rel=\"nofollow\">VIA</a></span> stock, giving a Buy rating today.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Jonathan Ho has given his Buy rating due to a combination of factors tied to Via’s operating momentum and growth visibility. He highlights that the company posted robust quarterly results, with record customer retention metrics and a 50% year-over-year expansion in its sales pipeline, which together counter market worries about the sustainability of its business model and growth trajectory.</p>\n<p></p>\n<p>Ho also emphasizes that fears around <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a>-related disruption and the roll-off of COVID-era stimulus appear overstated, noting Via’s defensible data and technology advantages as well as its mission-critical role in transit networks. In his view, the company’s growing use of AI, the potential upside from autonomous vehicles reducing driver-cost pressures, and new opportunities such as Via AI Labs expanding its addressable market all support a favorable risk-reward profile and justify a Buy rating.</p>\n<p>In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $37.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_137090738-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/via-strong-operating-momentum-defensible-ai-driven-transit-platform-and-expanding-growth-opportunities-justify-buy-rating-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 04:15:25",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991514,
            "title": "Hold Rating Maintained as Premium Valuation Caps Upside Despite Improved Fundamentals",
            "description": "<html><head></head><body><p><a href=\"https://www.tipranks.com/experts/analysts/michael-lewis\" target=\"_blank\" style=\"color:blue\">Michael Lewis</a>, an analyst from Truist Financial, maintained the Hold rating on Simon Property. The associated price target was raised to $196.00.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Michael Lewis has given his Hold rating due to a combination of factors, including modest upside to his new price target and an already full valuation. He raised his funds-from-operations outlook for 2026 and 2027 on stronger-than-expected property income and healthy underlying metrics such as traffic, tenant sales, and leasing demand, even while acknowledging somewhat higher interest costs.</p>\n<p>At the same time, his valuation work shows the shares trading at a sizable premium to Simon Property’s net asset value and above the company’s historical FFO multiples, which limits prospective total return. His updated $196 target price, derived from a mix of discounted cash flow, NAV premium, and FFO-based metrics, implies only a low single‑digit total return including the dividend, leading him to maintain a neutral, or Hold, stance despite the improved fundamental outlook.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/shutterstock_1347656177-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/hold-rating-maintained-as-premium-valuation-caps-upside-despite-improved-fundamentals-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 03:55:36",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991109,
            "title": "kneat.com (KSI) Receives a Buy from Stifel Nicolaus",
            "description": "<html><head></head><body><p><a data-autolink=\"true\" href=\"https://www.tipranks.com/experts/firms/stifel-nicolaus\">Stifel Nicolaus</a> analyst <a href=\"https://www.tipranks.com/experts/analysts/justin-keywood\" target=\"_blank\" style=\"color:blue\">Justin Keywood</a> maintained a Buy rating on kneat.com yesterday and set a price target of C$5.50.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, kneat.com, and HLS Therapeutics Inc. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Keywood has an average return of <span style=\"color:red;font-weight:bold;\">-3.9%</span> and a 48.33% success rate on recommended stocks. </p>\n<p>In addition to Stifel Nicolaus, kneat.com also received a Buy from CIBC’s Erin Kyle in a report issued today. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on kneat.com (TSX: KSI).</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1110645284-750x406.jpg",
            "link": "https://www.tipranks.com/news/blurbs/kneat-com-ksi-receives-a-buy-from-stifel-nicolaus-blurbs-news-2",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 01:55:22",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991138,
            "title": "Equinix: Strategic atNorth Acquisition Expands Nordic Scale and Enhances AFFO Accretion",
            "description": "<html><head></head><body><p>Analyst <a href=\"https://www.tipranks.com/experts/analysts/ari-klein\" target=\"_blank\" style=\"color:blue\">Ari Klein</a> from BMO Capital maintained a Buy rating on Equinix and keeping the price target at $1,050.00.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Ari Klein has given his Buy rating due to a combination of factors, primarily the strategic acquisition of atNorth, which significantly expands Equinix’s footprint in the Nordic data center market and aligns with its “build bigger” growth strategy. The transaction adds roughly 800MW of installed and development capacity, enhancing the company’s ability to serve rising demand for large-scale, infrastructure‑intensive workloads.</p>\n<p></p>\n<p>In addition, Klein notes that the atNorth deal is expected to be immediately accretive to adjusted funds from operations, supported by an attractive valuation multiple and a robust $4.2B financing package. He also highlights the strong improvement in atNorth’s contracted EBITDA over the past four years and the additional fee income Equinix will earn from its joint‑venture structure, all of which support the positive risk‑reward profile for EQIX shares.</p>\n<p>In another report released on February 25, Evercore ISI also maintained a Buy rating on the stock with a $1,060.00 price target.</p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/shutterstock_1030918024-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/equinix-strategic-atnorth-acquisition-expands-nordic-scale-and-enhances-affo-accretion-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 02:05:29",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991479,
            "title": "Viewing TE’s 19% Pullback as Technical, Not Fundamental, Creates Attractive Buy Entry Ahead of G2 and Earnings Catalysts",
            "description": "<html><head></head><body><p>In a report released today, <a href=\"https://www.tipranks.com/experts/analysts/sean-milligan\" target=\"_blank\" style=\"color:blue\">Sean Milligan</a> from Needham maintained a Buy rating on T1 Energy, with a price target of <span id=\"expert-recommendation-target\">$10.00</span>.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Sean Milligan has given his Buy rating due to a combination of factors, primarily viewing the recent 19% pullback in TE as driven by technical flows rather than a deterioration in company fundamentals. He notes that the stock had strongly outperformed while peers like SHLS, EOSE, and ARRY sold off on weak earnings, and reads the sharp decline as a “sell-the-winners” catch-up move and retail unwinding, rather than a reaction to any company-specific negative development.</p>\n<p>Milligan also emphasizes that the commentary around FSLR’s intellectual property is unlikely to be the direct cause of the move, reinforcing his view that fundamentals remain intact. Looking ahead, he highlights upcoming catalysts including late-March earnings, progress on G2 Phase 1 financing that could improve balance-sheet flexibility, and additional G2 offtake visibility, concluding that successful execution on these items represents meaningful upside and makes current weakness an attractive entry point.\n</p>\n<p>Milligan covers the Technology sector, focusing on stocks such as First Solar, Shoals Technologies Group, and Nextpower Inc. According to <a href=\"https://www.tipranks.com\" target=\"_blank\" style=\"color:blue\">TipRanks</a>, Milligan has an average return of <span style=\"color:red;font-weight:bold;\">-1.0%</span> and a 58.33% success rate on recommended stocks. </p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Industrials-5-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/viewing-tes-19-pullback-as-technical-not-fundamental-creates-attractive-buy-entry-ahead-of-g2-and-earnings-catalysts-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 03:15:26",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2991466,
            "title": "ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon",
            "description": "<html><head></head><body><p>Analyst <a href=\"https://www.tipranks.com/experts/analysts/emily-bodnar\" target=\"_blank\" style=\"color:blue\">Emily Bodnar</a> of H.C. Wainwright maintained a Buy rating on Acrivon Therapeutics, Inc., retaining the price target of $19.00.</p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p>\n<p>Emily Bodnar has given his Buy rating due to a combination of factors tied to ACR-368’s emerging clinical profile in serous endometrial cancer and the program’s registrational trajectory. She highlights that updated Phase 2b data show notably higher response rates in biomarker-selected and broader serous EC patients with limited prior therapy, alongside a safety profile largely confined to manageable, on-target hematologic effects without the gastrointestinal or neurologic toxicities often seen with other treatments.</p>\n<p></p>\n<p>She also points to strong enthusiasm from key opinion leaders, who view ACR-368 as a precision therapy with response rates that substantially exceed typical outcomes with current chemotherapy or post-immunotherapy options in this high‑mortality subset. In her view, the simplified, biopsy‑free Arm 3 design, ongoing U.S. and European enrollment, clear FDA alignment on the single‑arm registrational path, and the mechanistic rationale in HR‑deficient, p53‑mutated serous EC collectively support the potential for accelerated approval and meaningful upside for ACRV shares.</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1096459574-750x406.jpg",
            "link": "https://www.tipranks.com/news/ratings/acr-368-in-serous-endometrial-cancer-strong-phase-2b-efficacy-manageable-safety-and-a-clear-accelerated-approval-path-support-buy-rating-on-acrivon-ratings-news",
            "author": "TipRanks Auto-Generated Intelligence Newsdesk",
            "pub_date": "2026-02-28 03:05:33",
            "source": "tipranks_others",
            "kind": 1,
            "language": "en"
        }
    ]
}